Table 2

Mean flow-mediated dilation, brachial artery diameter, velocity-time integral, and blood pressure by dose (N = 21)

    Placebo

    1000 mg

    1500 mg

    2500 mg

    p-value1


FMD

Δ BAD, mm

0.18 (0.14)

0.16 (0.12)

0.14 (0.13)

0.17 (0.12)

0.54

FMD, %

5.3 (4.3)

5.0 (4.1)

4.3 (4.0)

4.9 (4.1)

0.59


BAD, mm

Resting

3.5 (0.7)

3.5 (0.8)

3.6 (0.8)

3.5 (0.8)

0.74

Hyperemia

3.7 (0.7)

3.6 (0.8)

3.7 (0.8)

3.7 (0.8)

-


VTI, cm

85.7 (20.8)

91.3 (19.5)

82.0 (21.4)

83.9 (18.0)

0.31


Blood Pressure, mm Hg

Systolic

129.4 (8.1)

130.7 (10.7)

131.1 (13.6)

132.0 (10.0)

0.33

Diastolic

82.8 (7.3)

81.8 (7.8)

83.0 (9.1)

82.3 (7.7)

0.72


1 p-value for modified linear contrast assessing dose-response from mixed effects linear model controlling for period and baseline response. Models for FMD also controlled for resting BAD.

All values expressed as mean (SD).

FMD - flow mediated dilation, BAD - brachial artery diameter, VTI - velocity-time integral

Asher et al. BMC Complementary and Alternative Medicine 2012 12:26   doi:10.1186/1472-6882-12-26

Open Data